GlaxoSmithKline PLC (NYSE:GSK)‘s stock had its “neutral” rating restated by J P Morgan Chase & Co in a research note issued to investors on Monday.

A number of other brokerages also recently issued reports on GSK. ValuEngine downgraded shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. TheStreet raised shares of GlaxoSmithKline PLC from a “c” rating to a “b” rating in a research note on Friday, May 19th. Citigroup Inc. downgraded shares of GlaxoSmithKline PLC from a “buy” rating to a “neutral” rating in a research note on Wednesday, July 5th. Zacks Investment Research downgraded shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research note on Friday. Finally, Berenberg Bank raised shares of GlaxoSmithKline PLC from a “hold” rating to a “buy” rating in a research note on Friday, May 26th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and ten have given a buy rating to the company’s stock. GlaxoSmithKline PLC currently has a consensus rating of “Hold” and an average target price of $46.00.

GlaxoSmithKline PLC (NYSE:GSK) traded down 1.36% during mid-day trading on Monday, hitting $42.08. 1,164,773 shares of the stock were exchanged. The company has a market capitalization of $102.80 billion, a PE ratio of 47.07 and a beta of 1.05. GlaxoSmithKline PLC has a 52 week low of $37.20 and a 52 week high of $45.58. The stock’s 50-day moving average is $43.28 and its 200 day moving average is $41.70.

GlaxoSmithKline PLC (NYSE:GSK) last announced its quarterly earnings results on Wednesday, April 26th. The pharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.62. GlaxoSmithKline PLC had a net margin of 5.48% and a return on equity of 113.31%. The firm had revenue of $9.23 billion for the quarter, compared to the consensus estimate of $9.09 billion. On average, analysts anticipate that GlaxoSmithKline PLC will post $2.86 EPS for the current year.

TRADEMARK VIOLATION WARNING: This news story was reported by American Banking News and is owned by of American Banking News. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of United States and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/07/24/j-p-morgan-chase-co-reaffirms-neutral-rating-for-glaxosmithkline-plc-gsk-2.html.

A number of institutional investors have recently modified their holdings of the company. Bronfman E.L. Rothschild L.P. raised its position in shares of GlaxoSmithKline PLC by 45.4% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 2,410 shares of the pharmaceutical company’s stock worth $102,000 after buying an additional 753 shares during the period. Nelson Van Denburg & Campbell Wealth Management Group LLC raised its position in shares of GlaxoSmithKline PLC by 1,747.4% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 2,494 shares of the pharmaceutical company’s stock worth $105,000 after buying an additional 2,359 shares during the period. Proficio Capital Partners LLC raised its position in shares of GlaxoSmithKline PLC by 233.0% in the first quarter. Proficio Capital Partners LLC now owns 2,844 shares of the pharmaceutical company’s stock worth $122,000 after buying an additional 1,990 shares during the period. Heritage Trust Co acquired a new position in shares of GlaxoSmithKline PLC during the first quarter worth $123,000. Finally, Westwood Holdings Group Inc. raised its position in shares of GlaxoSmithKline PLC by 15.7% in the first quarter. Westwood Holdings Group Inc. now owns 2,950 shares of the pharmaceutical company’s stock worth $124,000 after buying an additional 400 shares during the period. 8.98% of the stock is owned by institutional investors and hedge funds.

About GlaxoSmithKline PLC

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.